Flash Finance

Gufic Biosciences LimitedGUFICBIOCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 13 quarters of data
Consolidated Standalone
₹404.50
MCap ₹4,056 Cr · P/E 55.1
Gufic Biosciences Limited — Stock analysis & AI research Gufic Biosciences Limited — Multibagger AI analysis Gufic Biosciences Limited — Seasonality — best & worst months Gufic Biosciences Limited — Technical indicators & charts Gufic Biosciences Limited — Technical setup — score, trend, support & resistance Gufic Biosciences Limited — Live exchange announcements
📋 Stocks With Strong Quarterly Results📋 High Promoter Holding Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹261 Cr
Sales · Jun 2026
+16.6% YoY
₹47 Cr
Operating Profit · Jun 2026
+40.0% YoY
17.9%
OPM % · Jun 2026
+20.1% YoY
₹22 Cr
Net Profit · Jun 2026
+70.7% YoY
₹2.22
EPS · Jun 2026
+70.8% YoY

📝 Gufic Biosciences Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Gufic Biosciences Limited reported revenue of ₹261 crore for the quarter ended June 2026 (Q1 FY27), up 16.6% from ₹224 crore in the same quarter last year, and up 3.5% sequentially over the March 2026 quarter.

Net profit rose 70.7% year-on-year to ₹22 crore, from ₹13 crore. Earnings per share (EPS) came in at ₹2.22.

Operating profit stood at ₹47 crore — an operating margin (OPM) of 17.9%, compared with 14.9% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Gufic Biosciences Limited posted revenue of ₹944 crore, a growth of 15.2% over FY25, with a net profit of ₹64 crore (down 7.7% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹981 crore with a net profit of ₹74 crore.

Valuation snapshot

At the current price of ₹404.50, GUFICBIO has a market capitalisation of ₹4,056 crore and a trailing P/E of about 55.1.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 14th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 72.50%, foreign institutional investors (FIIs) 0.46%, domestic institutional investors (DIIs) 3.68%, public shareholders 23.36% of Gufic Biosciences Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹4,056 Cr
Current Price ?
₹404.5
P/E ?
55.14above ind
Industry P/E ?
37.20
P/B ?
6.10
P/S ?
4.13
P/FCF ?
289.74
Enterprise Value ?
₹4,461 Cr
EV/EBITDA ?
27.13
PEG ?
N/A
Earnings Yield ?
3.0%
Dividend Yield ?
0.03%
Profitability & Returns
Sales (TTM) ?
₹981 Cr
OPM ?
16.8%
Profit after tax (TTM) ?
₹74 Cr
EPS (TTM) ?
₹7.34
ROCE ?
12.0%
ROE ?
11.1%
ROA ?
5.5%
Growth
Sales — latest qtr ?
₹261 Cr
PAT — latest qtr ?
₹22 Cr
YoY qtr sales growth ?
16.6%
YoY qtr profit growth ?
70.7%
Sales growth (3y) ?
N/A
Sales growth (5y) ?
N/A
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹405 Cr
Debt to Equity ?
0.61
Interest Coverage ?
3.3
Current Ratio ?
N/A
Ownership
Promoter holding ?
72.50%
Change in promoter holding ?
-0.01%
Pledged percentage ?
N/A
Market
Return 3 months ?
5.9%
Return 6 months ?
34.9%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 195215202195203204208205224237231252261 +16.6% +3.5%
Operating Profit 35393634363934263338334747 +40.0% -0.8%
Other Income 10011020121-10 -50.6% +145.8%
Interest 44345558910899 +0.9% +3.5%
Depreciation 4444445888888 -0.2% -3.7%
Profit Before Tax 28313027282926111723182930 +73.9% +3.6%
Net Profit 2123222021221981317122222 +70.7% +1.4%
EPS 2.132.392.232.002.082.171.930.771.301.681.242.182.22 +70.8% +1.8%
OPM % 18.2% 18.3% 18.1% 17.6% 17.6% 18.9% 16.3% 12.9% 14.9% 16.0% 14.3% 18.7% 17.9% +20.1% -4.3%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹820 Cr ₹944 Cr ₹981 Cr +15.2%
Operating Profit ₹135 Cr ₹151 Cr ₹164 Cr +12.2%
OPM % 16.43% 16.01% 16.76% -2.6%
NPM % 8.50% 6.81% 7.50% -19.9%
Other Income ₹4 Cr ₹3 Cr ₹2 Cr -21.8%
Depreciation ₹21 Cr ₹31 Cr ₹31 Cr +48.1%
Interest ₹23 Cr ₹36 Cr ₹36 Cr +56.5%
EBIT ₹114 Cr ₹120 Cr ₹133 Cr +5.5%
PBT ₹94 Cr ₹87 Cr ₹99 Cr -8.0%
Tax ₹24 Cr ₹15 Cr ₹19 Cr -37.5%
Net Profit ₹70 Cr ₹64 Cr ₹74 Cr -7.7%
EPS ₹6.95 ₹6.40 ₹7.32 -7.9%
Material Cost ₹400 Cr ₹357 Cr ₹374 Cr -10.7%
Employee Cost ₹127 Cr ₹114 Cr ₹119 Cr -10.6%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 3 periods)

Metric Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 101010 +0.0%
Reserves 523591655 +10.8%
Borrowings 333336405 +20.5%
Other Liabilities 227232273 +17.7%
Total Liabilities 1,0931,1691,342 +14.8%
Fixed Assets 159506491 -3.0%
CWIP 3072222 +0.0%
Investments 222 +0.0%
Other Assets 625640827 +29.2%
Total Assets 1,0931,1691,342 +14.8%

💧 Cash Flow (latest 3 periods)

Metric Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -712345 -63.4%
Cash from Investing Activity -102-71-31 +56.3%
Cash from Financing Activity 82-3732 +186.5%
Net Cash Flow -271546 +206.7%
Free Cash Flow -1165214 -73.1%
CFO/OP 13%107%38% -64.5%

➗ Ratios (latest 3 periods)

Metric Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 149140115 -17.9%
Inventory Days 188211281 +33.2%
Days Payable 156155172 +11.0%
Cash Conversion Cycle 181197224 +13.7%
Working Capital Days 979380 -14.0%
ROCE % —13%12% -7.7%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 72.51%72.50%72.50%72.50%72.50% +0.0%
FIIs 0.32%0.33%0.44%0.42%0.46% +9.5%
DIIs 3.38%3.66%3.74%3.83%3.68% -3.9%
Public 23.81%23.51%23.30%23.23%23.36% +0.6%
No. of Shareholders 31,87631,42030,36229,22329,753 +1.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Gufic Biosciences Limited's revenue in Q1 FY27?
Gufic Biosciences Limited reported revenue of ₹261 crore for the quarter ended June 2026 (Q1 FY27), up 16.6% from ₹224 crore in the same quarter last year, and up 3.5% sequentially over the March 2026 quarter.
What was Gufic Biosciences Limited's net profit in Q1 FY27?
Net profit rose 70.7% year-on-year to ₹22 crore, from ₹13 crore. Earnings per share (EPS) came in at ₹2.22.
What is GUFICBIO's market capitalisation and P/E ratio?
At the current price of ₹404.50, GUFICBIO has a market capitalisation of ₹4,056 crore and a trailing P/E of about 55.1.
Who owns Gufic Biosciences Limited? (shareholding pattern)
As of Jun 2026, promoters held 72.50%, foreign institutional investors (FIIs) 0.46%, domestic institutional investors (DIIs) 3.68%, public shareholders 23.36% of Gufic Biosciences Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI